Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Words of wisdom. Re: dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Parsons JK.

Eur Urol. 2013 Jul;64(1):167. doi: 10.1016/j.eururo.2013.04.022. No abstract available.

PMID:
23746318
2.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS.

Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24.

PMID:
22277570
3.

Dutasteride and active surveillance of low-risk prostate cancer.

Fleshner NE; REDEEM trial investigators.

Lancet. 2012 Apr 28;379(9826):1590. doi: 10.1016/S0140-6736(12)60678-3. Epub 2012 Apr 26. No abstract available.

PMID:
22541581
4.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

PMID:
23176897
6.

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH.

Eur Urol. 2011 Feb;59(2):183-90. doi: 10.1016/j.eururo.2010.09.035. Epub 2010 Dec 4. Review.

PMID:
21130560
7.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R.

Urology. 2014 Aug;84(2):393-9. doi: 10.1016/j.urology.2014.04.016. Epub 2014 Jun 7.

PMID:
24916669
8.

Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

Akaza H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H, Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T; REDUCE Study Group.

Jpn J Clin Oncol. 2011 Mar;41(3):417-23. doi: 10.1093/jjco/hyq221. Epub 2010 Dec 1.

9.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

Margel D, Nandy I, Wilson TH, Castro R, Fleshner N.

J Urol. 2013 Dec;190(6):2039-45. doi: 10.1016/j.juro.2013.06.051. Epub 2013 Jun 29.

PMID:
23820059
10.

[Dutasteride provides chemoprevention].

Werner F.

Aktuelle Urol. 2006 Sep;37(5 Suppl):18. German. No abstract available.

PMID:
23646395
11.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
12.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

PMID:
22658758
13.

MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging.

Robertson NL, Moore CM, Ambler G, Bott SR, Freeman A, Gambarota G, Jameson C, Mitra AV, Whitcher B, Winkler M, Kirkham A, Allen C, Emberton M.

Contemp Clin Trials. 2013 Jan;34(1):80-9. doi: 10.1016/j.cct.2012.10.003. Epub 2012 Oct 17.

PMID:
23085153
14.

What (if anything) to do about low-risk prostate cancer.

Parker C.

Lancet. 2012 Mar 24;379(9821):1078-80. doi: 10.1016/S0140-6736(12)60066-X. Epub 2012 Jan 24. No abstract available.

PMID:
22277569
15.

Dutasteride for the treatment of prostate-related conditions.

Slater S, Dumas C, Bubley G.

Expert Opin Drug Saf. 2012 Mar;11(2):325-30. doi: 10.1517/14740338.2012.658040. Epub 2012 Feb 8. Review.

PMID:
22316171
16.

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group.

Contemp Clin Trials. 2007 Nov;28(6):763-9. Epub 2007 May 29.

PMID:
17573244
17.

Words of wisdom: Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Tombal B, Lecouvet F.

Eur Urol. 2012 Jun;61(6):1265-6. doi: 10.1016/j.eururo.2012.03.028. No abstract available.

PMID:
22542091
18.

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.

Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.

PMID:
21820580
19.

Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.

Svatek RS, Lotan Y.

Cancer Prev Res (Phila). 2011 Feb;4(2):277-83. doi: 10.1158/1940-6207.CAPR-10-0200. Epub 2010 Dec 16.

20.

Prostate cancer chemoprevention with 5α-reductase inhibitors.

Nepple KG, Andriole GL.

Urol Oncol. 2012 Sep;30(5):553-4. No abstract available.

PMID:
23193568
Items per page

Supplemental Content

Write to the Help Desk